<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343912</url>
  </required_header>
  <id_info>
    <org_study_id>GDN 012/17</org_study_id>
    <nct_id>NCT03343912</nct_id>
  </id_info>
  <brief_title>Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings</brief_title>
  <official_title>Dose-response Study With Three Vaginal Rings With Different Doses of Estriol and Trimegestone: Effect on Progesterone and Estradiol Levels in Healthy Females With Childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galeno Desenvolvimento de Pesquisas Clínicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SocraTec R&amp;D GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galeno Desenvolvimento de Pesquisas Clínicas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is performed as proof of pharmacological action investigation by
      demonstration of ovulation inhibition (dose-response study) under treatment with three Test
      vaginal rings releasing varying doses of estriol (E3) and trimegestone (TMG).

      Blood samples for determination of estradiol (E2) and progesterone (PG) levels will serve as
      pharmacodynamic surrogate parameters for characterization of the treatment effect on the
      endogenous hormones.

      Blood samples for determination of E3 and TMG in plasma will be collected in order to
      characterize pharmacokinetic parameters.

      Additionally, local tolerability characterized by gynecological inspection of the vaginal
      mucosa prior to and after insertion of the Investigational Medicinal Product (IMPs) is
      planned to be assessed
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMPs, releasing either 0.400 mg E3 and 0.06 mg TMG, or 0.300 mg E3 and 0.12 mg TMG, or
      0.200 mg E3 and 0.18 mg TMG per 24 h, will be applied intravaginally and remain in the vagina
      for the subsequent 21 days (single dose, 1 treatment cycle). A total of 36 female subjects,
      12 per treatment group, are intended to be randomized.

      Blood samples for determination of E2 and PG levels will be collected during treatment and
      until 20 days after removal of the ring. Blood samples for determination of E3 and TMG in
      plasma will be collected over the treatment period and until 48 h after removal of the ring.

      Bleeding intensity will also be documented during treatment and until 20 days after removal
      of the vaginal ring in a diary to characterize the effects of the different treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single centre, open-label, randomized (assignment to treatment group), parallel-group, three-arm single-dose clinical trial with application performed over 1 treatment cycle of 21 days.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of E2 and PG plasma levels</measure>
    <time_frame>0 - 41 days</time_frame>
    <description>Blood sampling for the determination of plasma levels of E2 and PG, in participants of each treatment group, as surrogate variables for treatment response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of E3 and TMG plasma levels</measure>
    <time_frame>0 - 23 days</time_frame>
    <description>Blood sampling for the determination of plasma levels of E3 and TMG, in participants of each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding intensity</measure>
    <time_frame>start of treatment until 42 days after treatment</time_frame>
    <description>Bleeding intensity, graded as &quot;no bleeding&quot;, &quot;spotting&quot; or &quot;bleeding&quot; as recorded in diary by the subject on a daily basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events per participant</measure>
    <time_frame>up to 42 days after treatment</time_frame>
    <description>Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of E3 and TMG</measure>
    <time_frame>0 - 23 days</time_frame>
    <description>Determination of Cmax for E3 and for TMG, based on plasma concentrations of samples obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for E3 and TMG</measure>
    <time_frame>0 - 23 days</time_frame>
    <description>Calculation of the AUC for E3 and for TMG, based on plasma concentrations of samples obtained</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Test 1 vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2 vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 3 vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol 0.400 mg/day and Trimegestone 0.06 mg/day</intervention_name>
    <description>Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application</description>
    <arm_group_label>Test 1 vaginal ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol 0.300 mg/day and Trimegestone 0.12 mg/day</intervention_name>
    <description>Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application</description>
    <arm_group_label>Test 2 vaginal ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol 0.200 mg/day and Trimegestone 0.18 mg/day</intervention_name>
    <description>Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application</description>
    <arm_group_label>Test 3 vaginal ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Under treatment with a commercially available combined oral contraceptive containing
             30 µg ethinylestradiol (EE) and 150 µg levonorgestrel (LVN) for the last 3 months
             prior to enrolment

          -  Body-mass index (BMI): ≥ 18.5 kg/m² and ≤ 30.0 kg/m²

          -  Good state of health

          -  Non-smoker, ex-smoker for at least 3 months

          -  Regular menstrual cycle with a length between 21 and 35 days

          -  Written informed consent, after having been informed about benefits and potential
             risks of the clinical trial

        Exclusion Criteria:

          -  Existing diseases or pathological findings, which might interfere with the safety or
             tolerability, and/or pharmacokinetics of the IMPs

          -  Subjects with severe allergies or multiple drug allergies

          -  Positive anti human immunodeficiency virus (anti-HIV) test, hepatitis B surface
             antigen (HBs-AG) test or anti hepatitis C virus (anti-HCV) test

          -  Presence or history of venous or arterial thrombosis, cerebrovascular accident, or
             increased risk of thrombosis

          -  Diabetes mellitus

          -  Unclarified vaginal bleeding or frequent infections of the urogenital tract

          -  Severe or chronic constipation

          -  Presence or history of migraine

          -  Drug or alcohol dependence

          -  Blood donation or other blood loss of more than 400 ml within the last 3 months

          -  Participation in a clinical trial during the last 6 months

          -  Pregnant or lactating women

          -  Subjects who do not agree to apply a barrier method for contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilberto De Nucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilberto De Nucci, MD</last_name>
    <phone>+55 19 9 9178-8879</phone>
    <email>denucci@gilbertodenucci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilberto De Nucci, MD</last_name>
      <phone>+5519991798879</phone>
      <email>denucci@gilbertodenucci.com</email>
    </contact>
    <investigator>
      <last_name>Gilberto De Nucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Galeno Desenvolvimento de Pesquisas Clínicas</investigator_affiliation>
    <investigator_full_name>Gilberto De Nucci</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Estriol</keyword>
  <keyword>Trimegestone</keyword>
  <keyword>Vaginal Ring</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

